Ontology highlight
ABSTRACT:
SUBMITTER: Leijen S
PROVIDER: S-EPMC7845944 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
Leijen Suzanne S van Geel Robin M J M RM Pavlick Anna C AC Tibes Raoul R Rosen Lee L Razak Albiruni R Abdul AR Lam Raymond R Demuth Tim T Rose Shelonitda S Lee Mark A MA Freshwater Tomoko T Shumway Stuart S Liang Li Wen LW Oza Amit M AM Schellens Jan H M JH Shapiro Geoffrey I GI
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20161031 36
Purpose AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemotherapy in patients with refractory solid tumors. Patients and Methods In part 1, patients received a single dose of AZD1775 followed by 14 days of observation. In part 2, patients received AZD1775 as a sin ...[more]